Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

asparaginase Erwinia chrysanthemi-rywn

View Patient Information
A recombinant form of asparaginase derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration, asparaginase Erwinia chrysanthemi-rywn hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase Erwinia chrysanthemi can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:asparaginase Erwinia chrysanthemi
asparaginase Erwinia chrysanthemi (recombinant)-rywn
crisantaspase
crisantaspase biobetter JZP-458
crisantaspasum
RC-P JZP-458
recombinant asparaginase Erwinia chrysanthemi JZP-458
recombinant crisantaspase JZP-458
recombinant Erwinia asparaginase JZP-458
US brand name:Erwinaze
Rylaze
Foreign brand name:Erwinase
Code name:JZP 458
JZP-458
JZP458
PF743
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search